-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Vicriviroc maleate
Category | Human immunodeficiency Virus (HIV) |
CAS | 599179-03-0 |
Description | Vicriviroc maleate is a CCR5 antagonist. |
Product Information
Synonyms | 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-piperidine (2Z)-2-butenedioate (1:1) |
IUPAC Name | (Z)-but-2-enedioic acid;(4,6-dimethylpyrimidin-5-yl)-[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl]methanone |
Molecular Weight | 649.7 |
Molecular Formula | C32H42F3N5O6 |
Canonical SMILES | CC1CN(CCN1C(COC)C2=CC=C(C=C2)C(F)(F)F)C3(CCN(CC3)C(=O)C4=C(N=CN=C4C)C)C.C(=CC(=O)O)C(=O)O |
InChI | 1S/C28H38F3N5O2.C4H4O4/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3;5-3(6)1-2-4(7)8/h6-9,18-19,24H,10-17H2,1-5H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t19-,24-;/m0./s1 |
InChIKey | GXINKQQWHLIBJA-UCIBKFKQSA-N |
Boiling Point | 608.1°C at 760mmHg |
Melting Point | >177°C (dec.) |
Purity | ≥98% (HPLC) |
Solubility | 10 mM in DMSO |
Appearance | White to Off-White Solid |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Complexity | 892 |
Exact Mass | 649.30871856 |
In Vitro | Vicriviroc (Sch-417690/Sch-D) is a potent, selective and oral bioavailable inhibitor of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC90s of 3.3 (JrFL), 2.8 (ADA-M), 1.8 (301657), 4.9 (JV1083) and 10 nM (RU 570). In addition, Vicriviroc shows a mean IC50 and IC90 of 0.45 nM and 4 nM for a panel of HIV isolates, and has weak activity against hERG activity (IC50, 5.8 μM). Vicriviroc inhibits chemotactic response to MIP-1α with IC50 values below 1 nM, and suppresses RANTES-induced signaling with a mean IC50 of 4.2 ± 1.3 nM. Vicriviroc potently suppresses all the viral isolates tested, with geometric mean EC50s of 0.04-2.3 nM and IC90s of 0.45-18 nM. |
In Vivo | Vicriviroc (10 mg/kg) has good oral availablity in rats and monkeys, with no acute CNS or GI effects in rats. |
PSA | 136.40000 |
Target | CCR5:2.5 nM (Ki) HIV-1 (301657):1.8 nM (IC90, in PBMC cells) HIV-1 (ADA-M):2.8 nM (IC90, in PBMC cells) HIV-1 (JrFL):3.3 nM (IC90, in PBMC cells) HIV-1 (JV1083):4.9 nM (IC90, in PBMC cells) HIV-1 (RU 570):10 nM (IC90, in PBMC cells) |